"Peptidomimetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that are designed to mimic the 3D structure of a natural peptide or protein.
| Descriptor ID |
D057786
|
| MeSH Number(s) |
D27.505.519.828
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Peptidomimetics".
Below are MeSH descriptors whose meaning is more specific than "Peptidomimetics".
This graph shows the total number of publications written about "Peptidomimetics" by people in this website by year, and whether "Peptidomimetics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Peptidomimetics" by people in Profiles.
-
Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors. Bioorg Med Chem Lett. 2021 10 15; 50:128333.
-
Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro). J Med Chem. 2022 02 24; 65(4):2880-2904.
-
3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. J Med Chem. 2022 02 24; 65(4):2926-2939.
-
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease. Biochem J. 2021 07 16; 478(13):2499-2515.
-
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors. Bioorg Med Chem Lett. 2021 09 15; 48:128263.
-
Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors. Bioorg Med Chem. 2021 09 15; 46:116301.
-
Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics. Cell Rep. 2021 06 29; 35(13):109305.
-
SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. Biomolecules. 2021 04 19; 11(4).
-
Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2. Expert Rev Anti Infect Ther. 2021 10; 19(10):1205-1217.
-
Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease. Phys Chem Chem Phys. 2021 Mar 21; 23(11):6746-6757.